NCT03710057View on ClinicalTrials.gov

Effect of Ivabradine in Lowering Heart Rate and Quality of Life in Chronic Heart Failure Patients

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

February 14, 2017

Study Completion Date

May 15, 2017

Conditions

Chronic Heart Failure

Interventions

DRUG

Ivabradine

A prospective, post-marketing observational study was conducted in National Institute of cardiovascular disease, Karachi-Pakistan. Total 50 patients were advised to take 5 mg Ivabradine (SIVAB) twice daily for 8 weeks.